Clinical trials: Human Blood Cell Disorders
Acquired Immunodeficiency Syndrome, HIV Infection
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
Synthetic HIV Peptide Vaccines (Treatment Protocol) We are conducting a study to evaluate the safety of two peptide vaccines (given alone or in combination) in patients with early HIV infection.
- Trial name
- NCT00001386
- Testing
- PCLUS 3-18 MN, PCLUS 6.1 MN
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640…
- Trial name
- ABC-102 (NCT02229981)
- Testing
- ABC294640
- Where
- United States
- Sponsor
- RedHill Biopharma Limited
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer
- Trial name
- NCT05153330
- Testing
- BMF-219
- Where
- 41 sites in United States, Greece and 3 more
- Volunteers
- 55 people
- Sponsor
- Biomea Fusion Inc.
HIV Infections
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
The aim of this trial is to find out if immune responses to HIV can be boosted in individuals who start medicines soon after being infected.
- Trial name
- NCT00058734
- Testing
- Dendritic Cells Pulsed with HIV antigens
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatocellular Carcinoma, Liver Cancer, Adult
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT05195294
- Testing
- LioCyx-M, Lenvatinib
- Volunteers
- 55 people
- Sponsor
- Lion TCR Pte. Ltd.
Prostate Cancer
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Androgen (a male sex hormone) deprivation is the standard therapy for metastatic prostate cancer and results in regression or control of disease in 80-85% of patients.
- Trial name
- NCT00122005
- Testing
- GM-CSF gene transduced allogeneic vaccine GVAX
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Providence Health & Services
Multiple Myeloma
Vaccination With PD-L1 Peptide Against Multiple Myeloma
Title: Vaccination with PD-L1 peptide with Montanide against multiple myeloma after high dose chemotherapy with stem cell support. A phase I first-in-human study.
- Trial name
- NCT03042793
- Testing
- PD-L1 peptide vaccine
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Lene Meldgaard Knudsen
HIV Infections
A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children
The purpose of this study is to determine the safety and maximum tolerated dose (the highest dose that can be given safely) of recombinant Interleukin-2 (rIL-2) in HIV-infected children.
- Trial name
- NCT00000849
- Testing
- Aldesleukin
- Where
- 14 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV - Anogenital Human Papilloma Virus Infection, HIV Infections
Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
Phase IV prospective study measuring the immunogenicity (neutralizing antibody titles against each HPV vaccine genotype) of the 9-valent vaccine against HPV (Gardasil9®Merck) in HIV-positive women aged 15-40 years with fully…
- Trial name
- Papillon (NCT03391921)
- Testing
- Vaccine
- Where
- Belgium
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Colorectal Cancer, Surgery
Human Blood Specimen Collection to Evaluate Immune Cell Function
Natural killer (NK) cells are leukocytes of the innate immune system and play a central role in the control of cancer metastases.
- Conditions
- Colorectal Cancer, Surgery, Perioperative Care
- Trial name
- NCT03422120
- Testing
- Natural Killer Cell Activity Assay
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Gastrointestinal Cancers, Breast Cancer
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
Background: Researchers want to test if certain cells can be re-programmed into stem cells. Stem cells can keep reproducing for a long time. Cells made by stem cells can be turned into different types of cells.
- Conditions
- Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer, Melanoma
- Trial name
- NCT03407040
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to…
- Trial name
- NCT00002674
- Testing
- filgrastim, cytarabine, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Hepatitis B
A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB
The purpose of this study is to investigate whether HB-Vac Activated-DCs Combined With Peg-IFN or NAs has more efficacy than Peg-IFN or NAs alone in the treatment of chronic hepatitis B patients
- Trial name
- NCT01935635
- Testing
- HPDCs-T immune therapy
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Myeloma-Multiple, Myeloma, Plasma-Cell
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
Background: Multiple myeloma is a cancer of the blood plasma cells. It usually becomes resistant to standard treatments. Researchers have developed a procedure called gene therapy.
- Trial name
- NCT03602612
- Testing
- Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Hepatitis B Infection
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03209037
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Ditan Hospital
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Anal Cancer, Nonneoplastic Condition
Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men
RATIONALE: Doctors use a swab to collect cell samples when testing for anal cancer and human papillomavirus. It is not yet known which type of swab is more effective in collecting cell samples for anal Pap tests and human…
- Conditions
- Anal Cancer, Nonneoplastic Condition, Precancerous Condition
- Trial name
- NCT00955591
- Testing
- Papanicolaou test
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma, Multiple Myeloma in Relapse
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07200089
- Testing
- NT-I7
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Non-Hodgkin Lymphoma, Multiple Myeloma
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and…
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease
- Trial name
- NCT05093335
- Testing
- [68Ga]-Pentixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center